These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
392 related articles for article (PubMed ID: 16849620)
21. Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction. Michalets EL; Smith LK; Van Tassel ED Ann Pharmacother; 1998; 32(7-8):761-5. PubMed ID: 9681092 [TBL] [Abstract][Full Text] [Related]
22. Cesium-induced QT-interval prolongation in an adolescent. O'Brien CE; Harik N; James LP; Seib PM; Stowe CD Pharmacotherapy; 2008 Aug; 28(8):1059-65. PubMed ID: 18657021 [TBL] [Abstract][Full Text] [Related]
23. Drug-induced long QT and torsade de pointes: recent advances. Kannankeril PJ; Roden DM Curr Opin Cardiol; 2007 Jan; 22(1):39-43. PubMed ID: 17143043 [TBL] [Abstract][Full Text] [Related]
24. Haloperidol-induced torsade de pointes. O'Brien JM; Rockwood RP; Suh KI Ann Pharmacother; 1999 Oct; 33(10):1046-50. PubMed ID: 10534216 [TBL] [Abstract][Full Text] [Related]
28. Fluconazole- and levofloxacin-induced torsades de pointes in an intensive care unit patient. Gandhi PJ; Menezes PA; Vu HT; Rivera AL; Ramaswamy K Am J Health Syst Pharm; 2003 Dec; 60(23):2479-83. PubMed ID: 14686224 [TBL] [Abstract][Full Text] [Related]
29. Torsades de Pointes ventricular tachycardia in a pediatric patient treated with fluconazole. Esch JJ; Kantoch MJ Pediatr Cardiol; 2008 Jan; 29(1):210-3. PubMed ID: 17849073 [TBL] [Abstract][Full Text] [Related]
30. Torsades de pointes associated with voriconazole use. Philips JA; Marty FM; Stone RM; Koplan BA; Katz JT; Baden LR Transpl Infect Dis; 2007 Mar; 9(1):33-6. PubMed ID: 17313469 [TBL] [Abstract][Full Text] [Related]
31. Diphenhydramine induced QT prolongation and torsade de pointes: An uncommon effect of a common drug. Husain Z; Hussain K; Nair R; Steinman R Cardiol J; 2010; 17(5):509-11. PubMed ID: 20865683 [TBL] [Abstract][Full Text] [Related]
32. Torsade de pointes: the clinical considerations. Gowda RM; Khan IA; Wilbur SL; Vasavada BC; Sacchi TJ Int J Cardiol; 2004 Jul; 96(1):1-6. PubMed ID: 15203254 [TBL] [Abstract][Full Text] [Related]
33. Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors. Amankwa K; Krishnan SC; Tisdale JE Clin Pharmacol Ther; 2004 Mar; 75(3):242-7. PubMed ID: 15001976 [TBL] [Abstract][Full Text] [Related]
34. Ciprofloxacin-induced torsade de pointes. Flanagan MC; Mitchell ES; Haigney MC Int J Cardiol; 2006 Nov; 113(2):239-41. PubMed ID: 16386810 [TBL] [Abstract][Full Text] [Related]
38. Torsades de pointes in a patient receiving fluconazole for cerebral cryptococcosis. McMahon JH; Grayson ML Am J Health Syst Pharm; 2008 Apr; 65(7):619-23. PubMed ID: 18359968 [TBL] [Abstract][Full Text] [Related]
39. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature. Lawrence KR; Nasraway SA Pharmacotherapy; 1997; 17(3):531-7. PubMed ID: 9165555 [TBL] [Abstract][Full Text] [Related]
40. [Torsade de pointes--a cause of Morgagni-Adam-Stokes attacks in patients with complete atrioventricular block]. Antonelli D; Rozner E; Freedberg NA; Turgeman Y Harefuah; 2008 Mar; 147(3):204-6, 279. PubMed ID: 18488859 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]